Ongoing research on treatments and/or causes of age-related macular degeneration (AMD) covers a wide range of approaches and paradigms.
The latest research published in the past three months includes:
The discovery of a new vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor;
The use of optical coherence tomography (OCT) to further delineate those who may need intensive treatment;
Societal influences on treatment.
Here is a summarize some of that latest research.
New inhibitor found
Researchers at Novartis describe a novel strategy for the use of in vivo models of choroidal neovascularization (CNV) that ultimately led to the discovery of acrizanib (LHA510). This small-molecule VEGFR-2 inhibitor has shown potency and efficacy in rodent CNV models, limited systemic exposure after topical ocular administration, multiple formulation options, and an acceptable rabbit ocular pharmacokinetic profile. It is too early to tell if this topical therapy will be successful enough to move into human trials.
Source: J Med Chem. 2018 Feb 5. doi: 10.1021/acs.jmedchem.7b01731. [Epub ahead of print]